Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLSM
Strong SellBlossomHill Therapeutics, Inc. · Healthcare · United States · $466M
9
StockRankGet insider-trade alerts
Q
31
V
25
M
25
P/E (TTM)
—
ROE
—
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
BlossomHill Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small-molecule medicines for oncology and autoimmune diseases. It operates as a research-driven entity, leveraging proprietary drug design platforms to create targeted therapies.
Loading 1Y...
PRICE (1Y)+22.2%
Close
$19.56
RSI (14)
75.7
SCORE BREAKDOWN
Quality
31
ROIC
-43.4%18.8
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%40.1
FCF/Assets
-29.4%14.7
Piotroski
239.9
Int. Cover
—N/A
D/E Ratio
0.22x48.8
Current Ratio
7.40x80.8
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-2.9x25.0
P/FCF
—N/A
P/B
-0.3x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$466M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLSM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLSM | BlossomHill Therapeutics, Inc.(you) | $466M | 9 | Strong Sell |
| EVMN | Evommune, Inc. | $496M | 9 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $532M | 8 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $404M | 8 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $510M | 12 | Strong Sell |
| CMPX | Compass Therapeutics, Inc. | $432M | 5 | Strong Sell |
| RGNX | REGENXBIO Inc. | $532M | 12 | Strong Sell |
| UPB | Upstream Bio, Inc. | $362M | 10 | Strong Sell |
| LYEL | Lyell Immunopharma, Inc. | $361M | 8 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $604M | 10 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%